Brian J. Day
Vice Chair of Research, Medicine Office of Research
Department of Medicine
Division of Environmental & Occupational Health Sciences
  • 5280 Top Doctors 2016
  • Recognized as a 5280 Top Doctor
  • America’s Top Doctors 2015 — Castle Connolly, Medical, Ltd.
  • Recognized in America’s Top Doctors — Castle Connolly, Inc.
  • Best Doctors in America® 2015 — Best Doctors, Inc.
  • Recognized in Best Doctors in America® — Best Doctors, Inc.
  • America’s Top Doctors 2016 — Castle Connolly Medical, Ltd.
  • Research AreasResearch Areas

    Special Interests

    Research Interests

    Cystic Fibrosis, COPD, chronic beryllium disease, interstitial lung disease, sulfur mustard lung injury, drug development. Adaptive glutathione responses to cigarette smoke in COPD. (NIH RO1 HL084469-05) (Primary Investigator). Novel Antioxidant Therapeutics for Sulfur Mustard Toxicity. (NIH U54 ES015678-06) (Project 2 Leader). Modulation of lung inflammation by CFTR-dependent thiols. (Cystic Fibrosis Foundation Research Grant) (Primary Investigator). Targeting oxidative stress in chronic beryllium disease.(NIH RO1 ES017582-04) (Multiple Primary Investigator).


    Purdue University (W Lafayette, IN), PhD, Pharmacology and Toxicology
    University of Montana (Missoula, MT), BS with Honors, School of Pharmacy
    Duke University (Durham, NC), Post-doctoral Integrated Toxicology & Pulmonary Fellow

    Awards & Recognition

    Basic Sciences Section Head, Department of Medicine, National Jewish Health
    Chief Science Officer, Aeolus Pharmaceuticals
    Chairman, Board of Publications Committee, Mechanisms Specialty Section Councilor, Society of Toxicology
    NIH Study Section Member, LIRR

    Professional Memberships

    Society of Toxicology
    American Thoracic Society
    Society of Free Radical Biology and Medicine
    American Heart Association
    American Chemical Society


    Dobis, D.R., Sawyer R.T., Gillespie M.M., Huang J., Newman L.S., Maier L.A. and Day B.J. Modulation of Lymphocyte Proliferation by Antioxidants in Chronic Beryllium Disease. Am. J. Respir. Crit. Care Med. 177:1002-1011, 2008.

    Day, B.J. Antioxidants as potential therapeutics for lung fibrosis. Antiox Redox Sig,10:355-370, 2008.

    Kachadourian, R and Day, B.J. Flavonoid-induced glutathione depletion: potential implications for cancer treatment. Free Radic. Biol. Med. 41:65-76, 2006.

    Velsor, L.W., Kariya C.,Kachadourian, R., and Day, B.J. Mitochondrial oxidative stress in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am. J. Respir. Cell Mol. Biol. 35:579-586, 2006.

    Day BJ, van Heeckeren AM, Min E, and Velsor L. Role for CFTR in a glutathione response to bronchopulmonary pseudomonas infection. Infect Immun 72:2045-2051, 2004.

    Academic Affiliations

    Professor of Medicine, Pharmaceutical Sciences and Immunology, University of Colorado Denver
    Professor, Colorado School of Public Health, University of Colorado Denver

    Conflicts of Interest

    National Jewish Health physicians and scientists may collaborate with pharmaceutical or other industries to develop medical and scientific breakthroughs or to provide education on trends in quality medical practice and outcomes to physicians and health professionals around the country. National Jewish Health maintains a strict conflict of interest policy to ensure that all potential conflicts are clearly visible and that management plans are put in place in order to further innovation and education while ensuring the protection of our patients and the integrity of our research. National Jewish Health publicly discloses any payment to our physicians or scientists. View this faculty member’s industry relationships and collaborations.

    Contact Information

    • Office: 877.225.5654



    • National Jewish Health Main Campus
      1400 Jackson St.
      Denver, CO 80206

    Patient Ratings

    The Patient Rating score is an average of all responses to care provider related questions on our independent rating system, the Press Ganey Patient Satisfaction Survey.

    Responses are measured on a scale of 1 to 5, with 5 being the best score. Learn more about our patient satisfaction survey.


    Comments are collected in our Press Ganey Patient Satisfaction Surveys. Patients are de-identified to protect confidentiality and patient privacy. Learn more about our patient satisfaction survey.